Medicenna Announces Management Change and Appoints Experienced Development Advisory Committee

Author's Avatar
Jan 17, 2022

Phase 1/2 ABILITY study of MDNA11 remains on track for an update on additional safety pharmacokinetic (PK), and pharmacodynamic (PD) data in low-dose cohorts in Q1 2022 and initial efficacy results in mid-2022